Michael Gelband ExodusPoint Capital Management
Michael Gelband is a co-founder of ExodusPoint Capital Management, a multi-strategy hedge fund launched by veterans of larger alternative platforms. The firm pursues diversified strategies across asset classes with a focus on risk-managed absolute returns. Gelband’s firm is followed as part of the newer generation of multi-strategy complexes.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$689M |
| 2 |
Broadcom
AVGO
|
+$153M |
| 3 |
Walmart Inc
WMT
|
+$136M |
| 4 |
Amazon
AMZN
|
+$104M |
| 5 |
iShares Core S&P 500 ETF
IVV
|
+$102M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$71.5M |
| 2 |
Pinnacle West Capital
PNW
|
+$49.1M |
| 3 |
Procter & Gamble
PG
|
+$43.7M |
| 4 |
Chevron
CVX
|
+$43.1M |
| 5 |
Hershey
HSY
|
+$43M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.62% |
| 2 | Healthcare | 9.42% |
| 3 | Industrials | 7.55% |
| 4 | Financials | 6.82% |
| 5 | Consumer Discretionary | 6.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
NXRT
1326
NexPoint Residential Trust
NXRT
$624M
| $276K | ﹤0.01% |
9,184
-28,251
| -75% | -$866K |
|
|
PTRN
1327
Pattern Group Inc
PTRN
$3.86B
| $276K | ﹤0.01% |
23,911
-226,089
| -90% | -$3.29M |
|
|
NNE
1328
Nano Nuclear Energy
NNE
$987M
| $276K | ﹤0.01% |
+11,489
| New | +$440K |
|
1329
Stoneridge
SRI
$205M
| $272K | ﹤0.01% |
+47,029
| New | +$296K |
|
1330
Keros Therapeutics
KROS
$215M
| $272K | ﹤0.01% |
13,360
-9,615
| -42% | -$169K |
|
1331
Simulations Plus
SLP
$372M
| $272K | ﹤0.01% |
14,902
-45,126
| -75% | -$792K |
|
1332
Oil-Dri
ODC
$1.33B
| $271K | ﹤0.01% |
+5,540
| New | +$307K |
|
1333
Hawaiian Electric Industries
HE
$1.97B
| $270K | ﹤0.01% |
+21,950
| New | +$254K |
|
|
UHT
1334
Universal Health Realty Income Trust
UHT
$573M
| $269K | ﹤0.01% |
+6,869
| New | +$268K |
|
1335
B&G Foods
BGS
$284M
| $268K | ﹤0.01% |
62,324
-313,172
| -83% | -$1.4M |
|
1336
Metallus
MTUS
$793M
| $264K | ﹤0.01% |
+15,360
| New | +$263K |
|
1337
Navigator Holdings
NVGS
$1.36B
| $262K | ﹤0.01% |
+15,130
| New | +$253K |
|
1338
Lyell Immunopharma
LYEL
$370M
| $262K | ﹤0.01% |
+8,511
| New | +$190K |
|
1339
Rivian
RIVN
$24.4B
| $260K | ﹤0.01% |
13,209
-6,165
| -32% | -$97.9K |
|
1340
Telos
TLS
$336M
| $260K | ﹤0.01% |
+50,995
| New | +$318K |
|
1341
CALL
Global X Lithium & Battery Tech ETF
LIT
$1.65B
| $260K | ﹤0.01% |
+4,000
| New | +$247K |
|
1342
Boston Beer
SAM
$1.93B
| $258K | ﹤0.01% |
+1,322
| New | +$273K |
|
1343
PUT
Ciena
CIEN
$53.3B
| $257K | ﹤0.01% |
+1,100
| New | +$213K |
|
1344
Service Corp International
SCI
$11.5B
| $257K | ﹤0.01% |
3,298
-49,529
| -94% | -$3.96M |
|
1345
Owlet
OWLT
$151M
| $256K | ﹤0.01% |
+15,840
| New | +$180K |
|
|
AVBH
1346
Avidbank Holdings
AVBH
$358M
| $256K | ﹤0.01% |
+9,623
| New | +$250K |
|
1347
Kura Oncology
KURA
$1.13B
| $255K | ﹤0.01% |
24,553
+6,714
| +38% | +$70.4K |
|
|
DFTX
1348
Definium Therapeutics
DFTX
$5.87B
| $254K | ﹤0.01% |
+18,948
| New | +$234K |
|
1349
Graham Corp
GHM
$1.15B
| $253K | ﹤0.01% |
3,939
-5,680
| -59% | -$343K |
|
1350
ClearPoint Neuro
CLPT
$460M
| $252K | ﹤0.01% |
+18,450
| New | +$342K |
|
Similar funds
Michael Gelband's Q4 2025 Portfolio in Review
As of Q4 2025, Michael Gelband held 2,189 positions worth $12.7B, up 30% from $9.79B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Michael Gelband deployed $2.85B of net new capital in Q4 2025, opening 723 new positions and adding to 409 existing holdings. Its largest new stake was iShares Core S&P 500 ETF: 150,000 shares worth $103M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 15% a quarter earlier, followed by Healthcare and Industrials.
On the sell side, the largest reduction was Procter & Gamble, an estimated $43.7M trimmed.
- Michael Gelband's largest Q4 2025 buy was iShares Core S&P 500 ETF: 150,000 shares worth $103M.
- Michael Gelband added most to NVIDIA in Q4 2025, an estimated $689M increase.
- Michael Gelband's biggest Q4 2025 reduction was Procter & Gamble, cutting an estimated $43.7M.
- Michael Gelband fully exited Meta Platforms (Facebook) in Q4 2025, selling an estimated $71.5M.
- Michael Gelband's ten largest holdings make up 30% of its $12.7B portfolio in Q4 2025.
- Michael Gelband opened 723 new positions and closed 716 in Q4 2025.
- Michael Gelband's portfolio value rose 30% quarter-over-quarter to $12.7B.
Based on ExodusPoint Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.